DF/HCC Program Affiliation

DF/HCC Associations

Research Abstract

Publications

• Aghi M, Rabkin S, Martuza RL.Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.Clin Neurosurg 2006;53:65-76.
  17380741
• Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO.Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta.Cancer Gene Ther 2007 May;14(5):460-7.
  17304235
• Aghi M, Rabkin SD, Martuza RL.Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.Cancer Res 2007 Jan 15;6
  17234749
• Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.Clin Cancer
  17121900
• Martuza RL.Vestibular schwannoma.J Neurosurg 2006 Oct;105(4):526; discussion 526.
  17044552
• Kuroda T, Rabkin SD, Martuza RL.Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.Cancer Res 2006 Oct 15;66(20):10127-35.
  17047077
• Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.Mol Ther 2006 Dec;14(6):789-97.
  17045531
• Kuroda T, Martuza RL, Todo T, Rabkin SD.Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.BMC Biotechnol 2006;6:40.
  16995942
• Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL.Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.Cancer Gene Ther 2006 Mar;13(3):253-65.
  16179929